Aim: In ALSYMPCA, the first-in-class alpha-emitter Ra-223 had a highly favorable safety profile and was well tolerated (Parker et al. NEJM 2013) . Safety monitoring of Ra-223 is essential for a complete safety profile. Reported here are safety results of a post hoc analysis from an interim review of ∼1.5 years after the last pt's last injection. Methods: Pts were to enter designated follow-up starting 4 weeks after their last injection until 3 years after first injection. Pts were to be evaluated at 9 follow-up visits. Only adverse events (AEs) considered treatment (tx) related were reported. Long-term safety was assessed by specific diseases (acute myelogenous leukemia [AML], myelodysplastic syndrome [MDS], aplastic anemia [AA], new primary bone cancer, and new primary cancer in other organs). Results: Of 921 pts (Ra-223, n = 614; placebo [ pbo], n = 307), 574 entered follow-up (Ra-223, n = 406; pbo, n = 168). Median follow-up time was 10.4 months with Ra-223 and 7.6 months with pbo. In the safety population, 25/404 (6%) Ra-223 pts and 8/167 (5%) pbo pts had 37 tx-related AEs. Overall, myelosuppression incidence was ≤ 3%.
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